August 9, 2024 07:22 AM EDT
Deals
China
Pharma

Mer­ck pays $700M for clin­i­cal-stage CD3xCD19 bis­pe­cif­ic an­ti­body

Kyle LaHucik

Senior Reporter

Mer­ck is mak­ing its fourth ac­qui­si­tion of the year, this time buy­ing a sin­gle as­set from a Shang­hai-based can­cer drug de­vel­op­er.

The New Jer­sey phar­ma …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Ma­jor PBM re­forms fea­ture in Con­gress' year-end spend­ing bill

What Trump’s FTC picks mean for bio­phar­ma deal­mak­ing and PBMs

Up­dat­ed: Ver­tex’s non-opi­oid pill dis­ap­points in mid-stage chron­ic pain study

A service from the Financial Times